Wall Street analysts predict that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post $221.51 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from $211.20 million to $225.85 million. Alnylam Pharmaceuticals reported sales of $125.85 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 76%. The business is scheduled to report its next earnings results on Thursday, November 4th.
On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $861.11 million for the current financial year, with estimates ranging from $841.07 million to $881.34 million. For the next fiscal year, analysts expect that the business will post sales of $1.27 billion, with estimates ranging from $1.10 billion to $1.50 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Monday, August 2nd. The biopharmaceutical company reported ($1.61) EPS for the quarter, hitting analysts’ consensus estimates of ($1.61). The firm had revenue of $220.55 million during the quarter, compared to analysts’ expectations of $193.66 million. Alnylam Pharmaceuticals had a negative return on equity of 88.43% and a negative net margin of 128.96%. The firm’s quarterly revenue was up 112.1% compared to the same quarter last year. During the same quarter last year, the business posted ($1.67) EPS.
In related news, insider Akshay Vaishnaw sold 14,708 shares of the business’s stock in a transaction that occurred on Friday, June 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,573,900.00. Following the transaction, the insider now directly owns 24,953 shares of the company’s stock, valued at approximately $4,366,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Laurie Keating sold 6,812 shares of the business’s stock in a transaction that occurred on Monday, July 12th. The stock was sold at an average price of $178.96, for a total value of $1,219,075.52. Following the transaction, the executive vice president now directly owns 6,944 shares in the company, valued at $1,242,698.24. The disclosure for this sale can be found here. Insiders sold a total of 118,563 shares of company stock worth $23,030,536 over the last ninety days. Corporate insiders own 2.30% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Commerce Bank increased its holdings in Alnylam Pharmaceuticals by 0.9% during the 2nd quarter. Commerce Bank now owns 5,841 shares of the biopharmaceutical company’s stock worth $990,000 after purchasing an additional 53 shares during the last quarter. UBS Group AG increased its holdings in Alnylam Pharmaceuticals by 0.4% during the 1st quarter. UBS Group AG now owns 21,222 shares of the biopharmaceutical company’s stock worth $2,996,000 after purchasing an additional 82 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Alnylam Pharmaceuticals by 2.1% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 4,544 shares of the biopharmaceutical company’s stock worth $770,000 after purchasing an additional 95 shares during the last quarter. Toronto Dominion Bank increased its holdings in Alnylam Pharmaceuticals by 0.6% during the 2nd quarter. Toronto Dominion Bank now owns 15,790 shares of the biopharmaceutical company’s stock worth $2,677,000 after purchasing an additional 97 shares during the last quarter. Finally, CWM LLC increased its holdings in Alnylam Pharmaceuticals by 14.3% during the 1st quarter. CWM LLC now owns 800 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 93.34% of the company’s stock.
Alnylam Pharmaceuticals stock traded up $2.18 during midday trading on Tuesday, reaching $187.97. 401,741 shares of the company were exchanged, compared to its average volume of 636,962. The company has a market capitalization of $22.34 billion, a price-to-earnings ratio of -24.77 and a beta of 1.22. The firm’s 50-day simple moving average is $189.16 and its 200-day simple moving average is $161.23. Alnylam Pharmaceuticals has a 1 year low of $119.29 and a 1 year high of $209.73. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.76 and a current ratio of 4.91.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.
Featured Story: What are the advantages of the Stochastic Momentum Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.